Brokerages expect REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) to post $29.25 million in revenue for the current fiscal quarter, reports Zacks Investment Research. Three analysts provided earnings estimates for REGENXBIO, with the lowest sales estimate at $22.04 million and the highest estimate at $38.20 million. REGENXBIO recorded sales of $22.04 million in the same quarter last year, suggesting a positive year-over-year growth rate of 32.7%. The company is due to release its next quarterly results on Monday, January 1.
On average, analysts expect REGENXBIO to report annual revenue of $215.26 million for the current year, with estimates ranging from $102.47 million to $415.20 million. dollars. For next year, analysts expect the company to post sales of $193.62 million, with estimates ranging from $102.47 million to $321.07 million. Zacks Investment Research sales calculations are an average based on a survey of research analysts who provide coverage for REGENXBIO.
REGENXBIO (NASDAQ:RGNX – Get Rating) last released its quarterly earnings data on Tuesday, March 1. The biotech company reported earnings per share (EPS) of $6.67 for the quarter, beating analyst consensus estimates of $4.28 from $2.39. REGENXBIO achieved a net margin of 27.18% and a return on equity of 22.35%. The company posted revenue of $398.66 million for the quarter, compared to $255.76 million expected by analysts. In the same quarter of the previous year, the company achieved EPS of ($1.24). The company’s revenue increased by 1,759.0% year over year.
A number of equity research analysts have weighed in on RGNX shares recently. SVB Leerink lowered its price target on shares of REGENXBIO from $29.00 to $25.00 and set a “market performance” rating on the stock in a Wednesday, March 2 report. StockNews.com began covering REGENXBIO shares in a report on Thursday, March 31. They issued a “holding” rating on the stock. TheStreet upgraded shares of REGENXBIO from a “d” rating to a “c” rating in a Tuesday, March 1 report. Morgan Stanley raised its price target on REGENXBIO shares from $50.00 to $51.00 and gave the company an “overweight” rating in a Wednesday, March 23 research note. Finally, Chardan Capital reiterated a “buy” rating on REGENXBIO shares in a Monday, April 11 research note. Four equity research analysts gave the stock a hold rating, four gave the company a buy rating and one gave the company a high buy rating. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $45.88.
Major investors have recently been buying and selling stocks. Hennion & Walsh Asset Management Inc. increased its equity stake in REGENXBIO by 52.1% in Q3. Hennion & Walsh Asset Management Inc. now owns 30,888 shares of the biotech company worth $1,295,000 after purchasing an additional 10,576 shares during the period. The New York State Teachers’ Retirement System increased its holdings of REGENXBIO stock by 0.9% in Q4. The New York State Teachers’ Retirement System now owns 45,631 shares of the biotech company worth $1,492,000 after purchasing an additional 400 shares during the period. Assenagon Asset Management SA increased its stake in REGENXBIO shares by 101.6% in the 4th quarter. Assenagon Asset Management SA now owns 277,700 shares of the biotech company worth $9,081,000 after purchasing an additional 139,947 shares during the period. Comerica Bank increased its stake in REGENXBIO by 3.4% in the 3rd quarter. Comerica Bank now owns 32,298 shares of the biotech company valued at $1,167,000 after buying 1,072 more shares last quarter. Finally, Geode Capital Management LLC increased its stake in REGENXBIO by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 665,419 shares of the biotech company valued at $27,894,000 after buying 2,711 additional shares last quarter. 87.57% of the shares are currently held by institutional investors.
RGNX opened at $22.23 on Friday. REGENXBIO has a fifty-two week low of $22.03 and a fifty-two week high of $46.46. The company has a market capitalization of $955.58 million, a PE ratio of 10.34 and a beta of 1.12. The company’s 50-day moving average is $29.75 and its 200-day moving average is $30.44.
About REGENXBIO (Get a rating)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to treat genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to impact on the disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Get a Free Copy of Zacks Research Report on REGENXBIO (RGNX)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for REGENXBIO Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for REGENXBIO and related companies with MarketBeat.com’s free daily email newsletter.